Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository

[1]  K. Lees,et al.  The Effect of Time to Treatment on Outcome in Very Elderly Thrombolysed Stroke Patients , 2013, International journal of stroke : official journal of the International Stroke Society.

[2]  E. Mori,et al.  Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[3]  P. Sandercock,et al.  Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis , 2013, International Journal of Stroke.

[4]  George Howard,et al.  Population shifts and the future of stroke: forecasts of the future burden of stroke , 2012, Annals of the New York Academy of Sciences.

[5]  Geoff Cohen,et al.  The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial , 2012, The Lancet.

[6]  Geoff Cohen,et al.  Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis , 2012, The Lancet.

[7]  The benefi ts and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke ( the third international stroke trial [ IST-3 ] ) : a randomised controlled trial , 2012 .

[8]  H. Diener,et al.  Influence of Age on Outcome From Thrombolysis in Acute Stroke: A Controlled Comparison in Patients From the Virtual International Stroke Trials Archive (VISTA) , 2010, Stroke.

[9]  K. Lees,et al.  Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive , 2010, BMJ : British Medical Journal.

[10]  Elsa Azevedo,et al.  Intravenous Alteplase for Stroke in Those Older Than 80 Years Old , 2010, Stroke.

[11]  J. Grotta,et al.  Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke (ICTuS-L): Final Results , 2010, Stroke.

[12]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[13]  Tammy Hoffmann,et al.  Clinical Guidelines for Stroke Management 2010 , 2010 .

[14]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[15]  Gary A. Ford,et al.  Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. , 2008, Cerebrovascular diseases.

[16]  Keith Muir,et al.  Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial , 2008, The Lancet Neurology.

[17]  Werner Hacke,et al.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study , 2007, The Lancet.

[18]  Scott Hamilton,et al.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials , 2004, The Lancet.

[19]  Nan Hu,et al.  [Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction]. , 2003, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue.

[20]  J Carpenter,et al.  Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. , 2000, Statistics in medicine.

[21]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[22]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[23]  T. N. t-P. S. S. Group,et al.  Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. , 1997, Stroke.

[24]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[25]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[26]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[27]  J. Broderick,et al.  Pilot Randomized Trial of Tissue Plasminogen Activator in Acute Ischemic Stroke , 1993 .

[28]  J. Broderick,et al.  Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group. , 1993, Stroke.

[29]  T. Hayakawa,et al.  Intravenous Tissue Plasminogen Activator Ameliorates the Outcome of Hyperacute Embolic Stroke , 1993 .

[30]  A. Yamadori,et al.  Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke , 1992, Neurology.

[31]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .